The Role of Probiotic Therapy in Pediatric MASLD: Pathophysiological and Clinical Perspectives
Open Access
- 19 January 2026
- journal article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49, 67785
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the most common chronic liver disease in children, with its prevalence steadily increasing alongside the global epidemic of childhood obesity. Despite the growing scale of the problem, effective therapeutic strategies remain limited. Recently, an increasing evidence has highlighted the role of gut dysbiosis and gut-liver axis in the pathogenesis of MASLD, prompting interest in probiotics as a potential treatment. Available date indicate that probiotics may improve liver enzymes and reduce hepatic steatosis, suggesting their potential as an adjunctive therapy. Additional reported benefits include favorable modulation of appetite-regulating hormones (leptin, ghrelin), reductions in anti-peptidoglycan antibodies and increases in incretin hormone GLP-1. However, current date are constrained by substantial limitations, preventing definitive conclusions regarding probiotic efficacy. Therefore, further well-designed studies involving larger sample sizes, longer follow-up periods, and standardized assessment methods are required to fully determine the therapeutic value of probiotics in pediatric MASLD.Keywords
This publication has 31 references indexed in Scilit:
- Meta‐analysis: Histological severity of biopsy‐proven metabolic dysfunction‐associated steatotic liver disease in pediatric patientsJournal of Pediatric Gastroenterology and Nutrition, 2025
- Global Epidemiology and Implications of PNPLA3 I148M Variant in Metabolic Dysfunction–Associated Steatotic Liver Disease: A Systematic Review and Meta-analysisJournal of Clinical and Experimental Hepatology, 2024
- Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysisWorld Journal of Pediatrics, 2024
- Fibrosis and steatotic liver disease in US adolescents according to the new nomenclatureJournal of Pediatric Gastroenterology and Nutrition, 2024
- The effect of orlistat in the treatment of non-alcoholic fatty liver in adolescents with overweight and obeseEuropean Journal of Pediatrics, 2023
- The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trialsEuropean Journal of Pediatrics, 2023
- Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysisPharmacology & Therapeutics, 2022
- Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in childrenHepatology, 2022
- Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortalityJournal of Hepatology, 2021
- Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic testsNature Reviews Gastroenterology & Hepatology, 2021